

Sabrina Strano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5430579/publications.pdf>

Version: 2024-02-01

125
papers

7,644
citations

53794

45
h-index

54911

84
g-index

127
all docs

127
docs citations

127
times ranked

10333
citing authors

#	ARTICLE	IF	CITATIONS
1	CircPVT1: a pivotal circular node intersecting Long Non-Coding-PVT1 and c-MYC oncogenic signals. <i>Molecular Cancer</i> , 2022, 21, 33.	19.2	23
2	MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. <i>Communications Biology</i> , 2022, 5, .	4.4	8
3	YAP and TAZ: Monocorial and bicorial transcriptional co-activators in human cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188756.	7.4	9
4	YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer. <i>Cancer Letters</i> , 2021, 500, 51-63.	7.2	54
5	Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. <i>Cell Death and Differentiation</i> , 2021, 28, 1493-1511.	11.2	19
6	The Conundrum of Giglio Island: Unraveling the dynamics of an apparent resistance to COVID-19 â€œ A descriptive study. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1467-1471.	4.1	1
7	CircRNAs: role in human diseases and potential use as biomarkers. <i>Cell Death and Disease</i> , 2021, 12, 468.	6.3	191
8	Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 344.	8.6	9
9	Insights into Intra-Tumoral Heterogeneity: Transcriptional Profiling of Chemoresistant MPM Cell Subpopulations Reveals Involvement of NFkB and DNA Repair Pathways and Contributes a Prognostic Signature. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12071.	4.1	7
10	Oral mucositis: the hidden side of cancer therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 210.	8.6	146
11	Metformin: Metabolic Rewiring Faces Tumor Heterogeneity. <i>Cells</i> , 2020, 9, 2439.	4.1	22
12	TMPRSS2, a SARS-CoV-2 internalization protease is downregulated in head and neck cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 200.	8.6	25
13	Dihydroartemisinin: from malaria to the treatment of relapsing head and neck cancers. <i>Annals of Translational Medicine</i> , 2020, 8, 612-612.	1.7	3
14	Non-coding RNAs as Putative Biomarkers of Cancer-Associated Cachexia. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 257.	3.7	15
15	PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2956-2971.	7.0	33
16	Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. <i>Haematologica</i> , 2019, 104, 82-92.	3.5	24
17	Dropwort-induced metabolic reprogramming restrains YAP/TAZ/TEAD oncogenic axis in mesothelioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 349.	8.6	13
18	Targeting mutant p53 in cancer: the latest insights. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 290.	8.6	16

#	ARTICLE	IF	CITATIONS
19	The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2019, 11, 1347.	3.7	31
20	<sc>cTAZ</sc> : a safeguard factor of antiviral response. <i>EMBO Reports</i> , 2019, 20, .	4.5	0
21	miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 141.	8.6	55
22	The circ<sc>RNA</sc>“micro<sc>RNA</sc> code: emerging implications for cancer diagnosis and treatment. <i>Molecular Oncology</i> , 2019, 13, 669-680.	4.6	300
23	MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrnone and Diet in the ETiology of breast cancer prospective study. <i>Carcinogenesis</i> , 2018, 39, 98-108.	2.8	29
24	HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome. <i>Oncogene</i> , 2018, 37, 1369-1385.	5.9	19
25	MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration. <i>Carcinogenesis</i> , 2018, 39, 293-304.	2.8	32
26	Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model. <i>Scientific Reports</i> , 2018, 8, 13638.	3.3	14
27	Agave negatively regulates YAP and TAZ transcriptionally and post-translationally in osteosarcoma cell lines. <i>Cancer Letters</i> , 2018, 433, 18-32.	7.2	20
28	Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma. <i>Theranostics</i> , 2018, 8, 1850-1868.	10.0	65
29	YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting. <i>Cancers</i> , 2018, 10, 137.	3.7	89
30	MicroRNAs as Key Effectors in the p53 Network. <i>International Review of Cell and Molecular Biology</i> , 2017, 333, 51-90.	3.2	34
31	Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence. <i>Modern Pathology</i> , 2017, 30, 1387-1401.	5.5	44
32	Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities. <i>Cell Discovery</i> , 2017, 3, 17022.	6.7	59
33	<i>MCM7</i> and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. <i>Carcinogenesis</i> , 2017, 38, 64-75.	2.8	52
34	Melatonin and Hippo Pathway: Is There Existing Cross-Talk?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1913.	4.1	34
35	Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. <i>International Journal of Molecular Sciences</i> , 2017, 18, 961.	4.1	41
36	The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex. <i>Genome Biology</i> , 2017, 18, 237.	8.8	179

#	ARTICLE	IF	CITATIONS
37	MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. <i>Oncotarget</i> , 2017, 8, 29540-29557.	1.8	26
38	Oncogenic Intra-p53 Family Member Interactions in Human Cancers. <i>Frontiers in Oncology</i> , 2016, 6, 77.	2.8	59
39	<sc>YAP</sc> enhances the pro-proliferative transcriptional activity of mutant p53 proteins. <i>EMBO Reports</i> , 2016, 17, 188-201.	4.5	154
40	MicroRNA expression as predictor of local recurrence risk in oral squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E189-97.	2.0	45
41	Comet Assay in Cancer Chemoprevention. <i>Methods in Molecular Biology</i> , 2016, 1379, 99-105.	0.9	6
42	Cancer Gastric Chemoprevention: Isolation of Gastric Tumor-Initiating Cells. <i>Methods in Molecular Biology</i> , 2016, 1379, 129-137.	0.9	2
43	MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. <i>Seminars in Cell and Developmental Biology</i> , 2016, 50, 133-142.	5.0	27
44	Cancer Chemoprevention. <i>Methods in Molecular Biology</i> , 2016, 1379, v.	0.9	0
45	Antibody Array as a Tool for Screening of Natural Agents in Cancer Chemoprevention. <i>Methods in Molecular Biology</i> , 2016, 1379, 189-199.	0.9	2
46	Mir 145/143: tumor suppressor, oncogenic microenvironmental factor or ...both?. <i>Aging</i> , 2016, 8, 1153-1155.	3.1	10
47	Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. <i>Oncotarget</i> , 2016, 7, 20532-20548.	1.8	49
48	Cdx2 Polymorphism Affects the Activities of Vitamin D Receptor in Human Breast Cancer Cell Lines and Human Breast Carcinomas. <i>PLoS ONE</i> , 2015, 10, e0124894.	2.5	21
49	What biomarkers (if any) for precise medicine?. <i>Aging</i> , 2015, 7, 533-534.	3.1	4
50	Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. <i>Oncotarget</i> , 2015, 6, 5547-5566.	1.8	41
51	miR-181c associates with tumor relapse of high grade osteosarcoma. <i>Oncotarget</i> , 2015, 6, 13946-13961.	1.8	20
52	<i>Cynara scolymus</i> affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion. <i>Oncotarget</i> , 2015, 6, 18134-18150.	1.8	36
53	Epigenetic silencing of miR-145-5p contributes to brain metastasis. <i>Oncotarget</i> , 2015, 6, 35183-35201.	1.8	75
54	Metformin-induced metabolic reprogramming of chemoresistant ALDHbright breast cancer cells. <i>Oncotarget</i> , 2014, 5, 4129-4143.	1.8	40

#	ARTICLE	IF	CITATIONS
55	Transcriptional Regulation by Mutant p53 and Oncogenesis. <i>Sub-Cellular Biochemistry</i> , 2014, 85, 91-103.	2.4	24
56	Tumor suppressor microRNAs: A novel non-coding alliance against cancer. <i>FEBS Letters</i> , 2014, 588, 2639-2652.	2.8	58
57	Downregulation of microRNAs 145-3p and 145-5p Is a Long-term Predictor of Postmenopausal Breast Cancer Risk: The ORDET Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2471-2481.	2.5	24
58	MicroRNAs: short non-coding players in cancer chemoresistance. <i>Molecular and Cellular Therapies</i> , 2014, 2, 16.	0.2	31
59	VDR primary targets by genome-wide transcriptional profiling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 348-356.	2.5	36
60	microRNAs: short non-coding bullets of gain of function mutant p53 proteins. <i>Oncoscience</i> , 2014, 1, 427-433.	2.2	17
61	microRNAs and cancer metabolism reprogramming: the paradigm of metformin. <i>Annals of Translational Medicine</i> , 2014, 2, 58.	1.7	28
62	YAP and p73: A Matter of Mutual Specificity in Tumor Suppression. , 2013, , 147-172.		3
63	MicroRNA-181a/b: Novel biomarkers to stratify breast cancer patients for PARPi treatment. <i>Cell Cycle</i> , 2013, 12, 1823-1823.	2.6	5
64	Gender, mutant p53 and PML: A growing affaire in tumor suppression and oncogenesis. <i>Cell Cycle</i> , 2013, 12, 1824-1825.	2.6	7
65	Blockage of melatonin receptors impairs p53-mediated prevention of DNA damage accumulation. <i>Carcinogenesis</i> , 2013, 34, 1051-1061.	2.8	52
66	PML Surfs into HIPPO Tumor Suppressor Pathway. <i>Frontiers in Oncology</i> , 2013, 3, 36.	2.8	14
67	Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention. <i>Metabolites</i> , 2013, 3, 1051-1075.	2.9	26
68	Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention. <i>MicroRNA (Shariqah)</i> , Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.2	2
69	MYC Is Activated by USP2a-Mediated Modulation of MicroRNAs in Prostate Cancer. <i>Cancer Discovery</i> , 2012, 2, 236-247.	9.4	82
70	Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells. <i>Cell Cycle</i> , 2012, 11, 132-140.	2.6	27
71	miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. <i>Cell Death and Disease</i> , 2012, 3, e423-e423.	6.3	160
72	Hippo and <i>rassf1a</i> Pathways: A Growing Affair. <i>Molecular Biology International</i> , 2012, 2012, 1-12.	1.7	26

#	ARTICLE	IF	CITATIONS
73	miR-10b*, a master inhibitor of the cell cycle, is downregulated in human breast tumours. <i>EMBO Molecular Medicine</i> , 2012, 4, 1214-1229.	6.9	85
74	Melatonin triggers p53Ser phosphorylation and prevents DNA damage accumulation. <i>Oncogene</i> , 2012, 31, 2931-2942.	5.9	75
75	SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells. <i>Oncogene</i> , 2012, 31, 3148-3163.	5.9	153
76	MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. <i>Cell Death and Differentiation</i> , 2012, 19, 1038-1048.	11.2	136
77	Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. <i>Nature Communications</i> , 2012, 3, 865.	12.8	198
78	ChIP-on-Chip Analysis of <i>In Vivo</i> Mutant p53 Binding To Selected Gene Promoters. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 305-312.	2.0	36
79	The Hippo tumor suppressor pathway: a report on the second workshop on the Hippo tumor suppressor pathway™. <i>Cell Death and Differentiation</i> , 2011, 18, 1388-1390.	11.2	2
80	Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. <i>Cell Cycle</i> , 2011, 10, 4330-4340.	2.6	74
81	Omics Underpins Novel Clues on VDR Chemoprevention Target in Breast Cancer. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 337-346.	2.0	6
82	Allelic Expression Imbalance of TP53 Mutated and Polymorphic Alleles in Head and Neck Tumors. <i>OMICS A Journal of Integrative Biology</i> , 2011, 15, 375-381.	2.0	10
83	Urinary 6-Sulphatoxymelatonin Levels and Risk of Breast Cancer in Premenopausal Women: The ORDET Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 729-737.	2.5	60
84	Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. <i>Cell Cycle</i> , 2010, 9, 2464-2466.	2.6	12
85	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like and early progenitor-targeting drugs. <i>Cell Cycle</i> , 2010, 9, 2950-2959.	2.6	86
86	Stability strengthens oncogenic activity. <i>Cell Cycle</i> , 2010, 9, 1456-1465.	2.6	0
87	EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors. <i>Science Signaling</i> , 2010, 3, ra43.	3.6	100
88	ID4: a new player in the cancer arena. <i>Oncotarget</i> , 2010, 1, 48-58.	1.8	36
89	ID4: a new player in the cancer arena. <i>Oncotarget</i> , 2010, 1, 48-58.	1.8	25
90	Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like and early progenitor-targeting drugs. <i>Cell Cycle</i> , 2010, 9, 2878-87.	2.6	51

#	ARTICLE	IF	CITATIONS
91	Metformin, diet and breast cancer: An avenue for chemoprevention. <i>Cell Cycle</i> , 2009, 8, 2661-2661.	2.6	33
92	Tetraploidy triggers mitochondria. <i>Cell Cycle</i> , 2009, 8, 1305-1307.	2.6	0
93	YAP: At the crossroad between transformation and tumor suppression. <i>Cell Cycle</i> , 2009, 8, 49-57.	2.6	99
94	The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 1086-1093.	8.2	182
95	The Hippo Tumor Suppressor Pathway: A Brainstorming WorkshopA report on the research meeting "The Hippo Tumor Suppressor Pathway: A Brainstorming Workshop" sponsored mainly by the Regina Elena Cancer Center and the Nicola Foundation and held in Rome, Italy, on 22 and 23 April 2009.. <i>Science Signaling</i> , 2009, 2, nr6.	3.6	13
96	PML, YAP, and p73 Are Components of a Proapoptotic Autoregulatory Feedback Loop. <i>Molecular Cell</i> , 2008, 32, 803-814.	9.7	224
97	Urinary 6-Sulfatoxymelatonin Levels and Risk of Breast Cancer in Postmenopausal Women. <i>Journal of the National Cancer Institute</i> , 2008, 100, 898-905.	6.3	94
98	The disruption of the protein complex mutant p53/p73 increases selectively the response of tumor cells to anticancer drugs. <i>Cell Cycle</i> , 2008, 7, 3440-3447.	2.6	83
99	Oncogenomic Approaches in Exploring Gain of Function of Mutant p53. <i>Current Genomics</i> , 2008, 9, 200-207.	1.6	20
100	Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. <i>Cell Cycle</i> , 2008, 7, 1870-1879.	2.6	81
101	Mutant p53 Enhances Nuclear Factor κ B Activation by Tumor Necrosis Factor α in Cancer Cells. <i>Cancer Research</i> , 2007, 67, 2396-2401.	0.9	178
102	P73, P63 and Mutant P53: Members of Protein Complexes Floating in Cancer Cells. , 2007, , 223-232.		3
103	YAP1 Meets Tumor Suppression. <i>Molecular Cell</i> , 2007, 27, 863-864.	9.7	14
104	Mutant p53 proteins: Between loss and gain of function. <i>Head and Neck</i> , 2007, 29, 488-496.	2.0	45
105	Mutant p53: an oncogenic transcription factor. <i>Oncogene</i> , 2007, 26, 2212-2219.	5.9	241
106	p73, p63 and Mutant p53: Members of Protein Complexes Floating in Cancer Cells. , 2007, , 223-232.		0
107	Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. <i>Cancer Cell</i> , 2006, 10, 191-202.	16.8	386
108	E2F1 repressor controls selectively p53 family members during differentiation. <i>Oncogene</i> , 2005, 24, 7273-7280.	5.9	42

#	ARTICLE	IF	CITATIONS
109	A Role of p73 in Mitotic Exit. <i>Journal of Biological Chemistry</i> , 2005, 280, 30354-30360.	3.4	35
110	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. <i>Molecular Cell</i> , 2005, 18, 447-459.	9.7	318
111	The Transcriptional Coactivator Yes-Associated Protein Drives p73 Gene-Target Specificity in Response to DNA Damage. <i>Molecular Cell</i> , 2005, 19, 429.	9.7	3
112	p73-induced apoptosis: A question of compartments and cooperation. <i>Biochemical and Biophysical Research Communications</i> , 2005, 331, 688-693.	2.1	37
113	Pin1 Links the Activities of c-Abl and p300 in Regulating p73 Function. <i>Molecular Cell</i> , 2004, 14, 625-636.	9.7	165
114	v-Src inhibits myogenic differentiation by interfering with the regulatory network of muscle-specific transcriptional activators at multiple levels. <i>Oncogene</i> , 2003, 22, 8302-8315.	5.9	13
115	Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73. <i>Journal of Biological Chemistry</i> , 2003, 278, 10546-10555.	3.4	36
116	p73 Is Regulated by Phosphorylation at the G2/M Transition. <i>Journal of Biological Chemistry</i> , 2003, 278, 49196-49202.	3.4	37
117	p73-Mediated Chemosensitivity: A Preferential Target of Oncogenic Mutant p53. <i>Cell Cycle</i> , 2003, 2, 345-346.	2.6	34
118	p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53. <i>Cell Cycle</i> , 2003, 2, 348-9.	2.6	20
119	Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities. <i>Journal of Biological Chemistry</i> , 2002, 277, 18817-18826.	3.4	203
120	Identification of Direct p73 Target Genes Combining DNA Microarray and Chromatin Immunoprecipitation Analyses. <i>Journal of Biological Chemistry</i> , 2002, 277, 43359-43368.	3.4	125
121	From p63 to p53 across p73. <i>FEBS Letters</i> , 2001, 490, 163-170.	2.8	79
122	Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity. <i>Journal of Biological Chemistry</i> , 2001, 276, 15164-15173.	3.4	368
123	The Transcriptional Repressor ZEB Regulates p73 Expression at the Crossroad between Proliferation and Differentiation. <i>Molecular and Cellular Biology</i> , 2001, 21, 8461-8470.	2.3	117
124	Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73. <i>Journal of Biological Chemistry</i> , 2000, 275, 29503-29512.	3.4	217
125	Long non-coding RNA MALAT1 as metastasis suppressor. <i>Precision Cancer Medicine</i> , 0, 2, 4-4.	1.8	0